CANF
CANF clinical trials: Can-Fite BioPharma Ltd.
Every trial on ClinicalTrials.gov where Can-Fite BioPharma Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 22
- Trials linked
- 22
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CANF on the catalyst calendar · CANF registry changes
- Primary completion Aug 31, 2027Sponsor estimatePhase 2NCT07410455An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeCan-Fite BioPharma · Lowe SyndromeNot yet recruitingCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT06643260A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyCan-Fite BioPharma · Plaque PsoriasisNot yet recruitingCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2026Sponsor estimatePhase 3NCT05201404Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisCan-Fite BioPharma · Hepatocellular CarcinomaRecruitingCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2026Sponsor estimatePhase 2NCT06387342Namodenoson Treatment of Advanced Pancreatic CancerCan-Fite BioPharma · Pancreatic AdenocarcinomaRecruitingCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2025Sponsor estimatePhase 2NCT04697810Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)Can-Fite BioPharma · NASH - Nonalcoholic SteatohepatitisUnknown statusCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2007ActualPhase 2NCT00280917Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsCan-Fite BioPharma · Rheumatoid ArthritisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2009ActualPhase 2NCT00428974Safety and Efficacy Study of CF101 to Treat PsoriasisCan-Fite BioPharma · Plaque PsoriasisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2017ActualPhase 2NCT02128958Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)Can-Fite BioPharma · Hepatocellular CarcinomaCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2013ActualPhase 3NCT01235234Trial of CF101 to Treat Patients With Dry Eye DiseaseCan-Fite BioPharma · Keratoconjunctivitis SiccaCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2022ActualPhase 3NCT03168256CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCan-Fite BioPharma · Plaque PsoriasisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 2NCT01033422Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureCan-Fite BioPharma · Ocular HypertensionCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2013ActualPhase 2NCT01034306Oral CF101 Tablets Treatment in Patients With Rheumatoid ArthritisCan-Fite BioPharma · Rheumatoid ArthritisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2012ActualPhase 1/Phase 2NCT00790218A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular CarcinomaCan-Fite BioPharma · Hepatocellular CarcinomaCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2022ActualPhase 2NCT04333472Piclidenoson for Treatment of COVID-19Can-Fite BioPharma · COVID-19CompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2009ActualPhase 2NCT00349466Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis SiccaCan-Fite BioPharma · Keratoconjunctivitis SiccaCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2020ActualPhase 3NCT02647762CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisCan-Fite BioPharma · Rheumatoid ArthritisTerminatedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2/Phase 3NCT01265667Trial of CF101 to Treat Patients With PsoriasisCan-Fite BioPharma · Plaque PsoriasisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2020ActualPhase 2NCT02927314A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseCan-Fite BioPharma · Non-alcoholic Steatohepatitis (NASH)CompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 2NCT00556894Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis PatientsCan-Fite BioPharma · Rheumatoid ArthritisCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2019Sponsor estimatePhase 2NCT01905124Safety &Efficacy of CF101 to Subjects With UveitisCan-Fite BioPharma · Uveitis, PosteriorWithdrawnCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2018Sponsor estimatePhase 2NCT00837291A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the KneeCan-Fite BioPharma · Osteoarthritis of the KneeWithdrawnCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2011ActualPhase 1/Phase 2NCT00790673A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1Can-Fite BioPharma · Chronic Hepatitis CCompletedCANFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 22 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner